The QualityStocks Daily Monday, October 17th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(ACOR) $0.8970 +167.52%

MarketClub Analysis(LFG) $26.0200 +54.15%

Stocks to Buy Now(KAVL) $1.4300 +19.17%

The QualityStocks Daily Stock List

Inpixon (INPX)

StockMarketWatch, MarketClub Analysis, BUYINS.NET, QualityStocks, TraderPower, StreetInsider, Promotion Stock Secrets, InvestorPlace, MarketBeat, Buzz Stocks, HotOTC, Money Morning, PennyStockProphet, Zacks, StockOnion, The Online Investor and OTCtipReporter reported earlier on Inpixon (INPX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Inpixon (NASDAQ: INPX) (FRA: 1XS4) is an indoor intelligence firm which specializes in the capture, interpretation and contextualization of indoor data so that the users of that data can meaningfully act upon it. Inpixon was founded in 1999 and has its headquarters in Palo Alto, California.

The firm’s indoor intelligence platform collects a lot of data from IoT devices, 3rd party as well as proprietary sensors which are designed and installed to position and detect Wi-Fi, cellular, and Bluetooth devices. This system makes it possible for users to lower their costs, increase their revenue, and also enhance safety. Indoor spaces get smarter, more secure and safer with Inpixon.

Customers of the company can choose from a wide variety of Inpixon hardware and software. For example, the firm has the Inpixon Pod sensor which primarily caters to Wi-Fi devices; the Inpixon Sensor 4000 which can work with Wi-Fi, Bluetooth and cellular network devices; and Inpixon Sensor Extra which is suitable for devices running on Wi-Fi, BLE and UWB-powered devices. The firm earns money by selling the sensors and levying monthly user fees or from licensing fees depending on the specific sensors which a client opts for.

The solutions of Inpixon are useful to players in manufacturing, healthcare, hospitality, retail, governmental, corporate and other such industries. The firm has nurtured a top-notch ecosystem of partners that includes app developers, resellers, technology providers and integrations as it provides asset tracking, indoor wayfinding, indoor-outdoor navigation, geofencing, map profiles, device detection and so many other applications of the Inpixon product/service range.

Towards the end of April 2021, the firm announced that Gartner, a leading firm involved in conducting research as well as analysis of the global information tech industry, had named Inpixon among the leading firms in providing indoor location services. Such recognition positions the company to be a desirable provider of indoor technology services around the globe, and that would help to grow its operations and net earnings.

Inpixon (INPX), closed Monday's trading session at $9.11, up 90.5858%, on 33,650,413 volume. The average volume for the last 3 months is 127.924M and the stock's 52-week low/high is $4.17/$78.00.

Acorda Therapeutics (ACOR)

The Street, StreetInsider, Marketbeat, InvestorPlace, StockMarketWatch, SmarTrend Newsletters, Schaeffer's,, Zacks, BUYINS.NET, Daily Trade Alert, MarketClub Analysis, Penny Sleuth, Greenbackers, QualityStocks, Whiskey & Gunpowder, Daily Markets, Money Morning, Street Insider, Streetwise Reports, AllPennyStocks, TraderPower, Barchart, Hit and Run Candle Sticks, CNBC Breaking News, Average Joe Options, Darwin Investing Network, FNNO Newsletters, Investopedia, Momentum Traders, PowerRatings Stocks, News, Super Stock Picker, Trades Of The Day, WealthMakers and MarketWatch reported earlier on Acorda Therapeutics (ACOR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Acorda Therapeutics Inc. (NASDAQ: ACOR) (FRA: CDG0) is a biopharmaceutical firm that is engaged in the development and commercialization of therapies for neurological disorders in order to restore function and improve the lives of patients living with neurological disorders.

The firm is based in Ardsley, New York and was incorporated in 1995 by Ronald Cohen. It operates as part of the healthcare sector, under the biotech and pharma sub-industry and serves consumers across the globe.

The company is party to a license and collaboration agreement with Biogen Inc., which entails developing and commercializing of Ampyra. It is also developing multiple approaches for the repair and regeneration of the brain and spinal cord.

The enterprise’s products include a formulation known as CVT-301 (Inbrija), for treating OFF periods in patients with Parkinson’s disease; a formulation developed to treat alcohol dependence known as Selincro, and an oral drug developed to improve walking in patients who suffer from multiple sclerosis known as dalfampridine (Ampryra). In addition to this, it also develops Cimaglermin alfa (CVT-427), for heart failure patients; rHIgM22, which concluded phase 1 clinical trials evaluating its effectiveness in treating patients with multiple sclerosis and an ARCUS product for treating acute migraines. The enterprise markets Ampyra as Fampyra in the Americas, Asia and Europe.

The company recently entered into a distribution and supply agreement with Esteve Pharmaceuticals, which will allow it to commercialize its Inbrija formulation in Spain. This move will help extend the company’s consumer reach, which will have a positive effect on its growth and encourage more investments into the firm.

Acorda Therapeutics (ACOR), closed Monday's trading session at $0.897, up 167.5216%, on 130,421,394 volume. The average volume for the last 3 months is 31.743M and the stock's 52-week low/high is $0.2611/$4.83.

American Virtual Cloud Technologies (AVCT)

QualityStocks, Schaeffer's, MarketClub Analysis, StockMarketWatch, BUYINS.NET, The Stock Dork, TradersPro, The Street, The Online Investor, MarketBeat and FreeRealTime reported earlier on American Virtual Cloud Technologies (AVCT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American Virtual Cloud Technologies Inc. (NASDAQ: AVCT) is an IT solutions and managed services provider that is engaged in the provision of solutions and managed services which include enhanced connectivity, cybersecurity and unified cloud communications.

The firm has its headquarters in Atlanta, Georgia and was incorporated in 2016, on April 7th. It mainly serves consumers in the United States.

The company specializes in delivering solutions in Managed IT services, cybersecurity, cloud services, enterprise networking and data center transformation. It offers its services to different sectors which include technology service providers, retail and hospitality, public sector, manufacturing and logistics, health care, education, finance and the energy sector, among other sectors. Geographically, the company generates most of its revenue from the domestic market.

The enterprise delivers actionable outcomes for companies through the use of technology and IT solutions that drive innovation and business outcomes. Its services include hybrid and private data centers, enterprise networking services, storage, virtualization and managed IT services. Its products include servers, desktops and data storage, as well as network communications to help improve workplace communication, productivity and efficiency. It also provides software solutions and services, licensing management and licensing services which help consumers to optimize their software investments.

The company recently appointed a new CEO who is familiar with all aspects of the company’s operations and strategy and brings extensive industry experience to his role. The move will strengthen the company’s leadership and facilitate shareholder value creation as well as growth, which is bound to have a positive influence on investments into the firm.

American Virtual Cloud Technologies (AVCT), closed Monday's trading session at $2.24, up 39.1304%, on 31,742,783 volume. The average volume for the last 3 months is 119,132 and the stock's 52-week low/high is $1.21/$46.95.

Oxford Square Capital (OXSQ)

The Online Investor, MarketBeat, Zacks, Investors Alley, InvestorPlace, Trades Of The Day, TradersPro, TopStockAnalysts and Daily Trade Alert reported earlier on Oxford Square Capital (OXSQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Oxford Square Capital Corp (NASDAQ: OXSQ) (FRA: 22T) is a business development firm which operates as a non-diversified, closed-end management investment firm.

The firm has its headquarters in Greenwich, Connecticut and was incorporated in 2003. Prior to its name change, the firm was known as TICC Capital Corporation. It operates as part of the asset management industry, under the financial services sector. The firm serves consumers in the United States.

The company invests in both private and public companies. Its investment objective is to maximize the total return for its portfolio. It concentrates its investments on firms which have annual revenues of less than $200 million and/or an enterprise value or market capitalization of less than $300 million. For every transaction, it invests between $5 million - $30 million. The company is TICC’s investment adviser.

The private equity and mezzanine enterprise invests in subordinated debt, secured and unsecured senior debt, preferred stock, junior subordinated debt, syndicated bank loans and common stock. It mainly invests in debt and/or equity securities of technology-related companies that operate in the Internet, computer software, information technology infrastructure and services, telecommunications and telecommunications equipment, media, hardware, semiconductors, technology-enabled services, semiconductor capital equipment, diversified technology, medical device technology and networking systems sectors.

The firm, which recently released its latest financial results, remains focused on seeking attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation structured finance investments. This will generate additional revenues for the firm and create significant value for its shareholders.

Oxford Square Capital (OXSQ), closed Monday's trading session at $2.94, even for the day, on 119,215 volume. The average volume for the last 3 months is 81,713 and the stock's 52-week low/high is $2.82/$4.47.

Perpetua Resources (PPTA)

MarketBeat and FreeRealTime reported earlier on Perpetua Resources (PPTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Perpetua Resources Corp (NASDAQ: PPTA) (TSE: PPTA) (LON: 0V6R) (FRA: 9MIB) is an exploration and development-stage firm that is focused on exploring for and acquiring mineral properties with the intention of exploring, evaluating and placing into production.

The firm has its headquarters in Boise, Idaho and was incorporated in 2011, on February 22nd. Prior to its name change in February 2021, the firm was known as Midas Gold Corp. It operates as part of the other precious metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company is focused on gold mining and development projects. It operates through mineral exploration in the United States segment. The company’s subsidiaries include Idaho Gold Resources Company LLC and Perpetua Resources Idaho Inc.

The enterprise’s principal business is the exploration, re-development, restoration and operation of the Stibnite Gold Project. This project, which is 100% owned by the enterprise, is located in Valley County and contains gold-antimony-silver deposits. It is one of the highest-grade, open-pit gold deposits in the U.S. and has been designed to apply a responsible and modern mining approach to restore an abandoned mine site. This project produces gold and the only mined source of antimony in America.

The firm, which recently announced its latest financial results, received its first permit which marks a significant milestone for its Stibnite project. This move also brings it closer to achieving its goal to provide critical minerals for the country, which will bring in additional revenues and investments into the firm.

Perpetua Resources (PPTA), closed Monday's trading session at $1.74, off by 0.571429%, on 81,713 volume. The average volume for the last 3 months is 179,070 and the stock's 52-week low/high is $1.73/$5.938.

Five Point Holdings (FPH)

MarketBeat, StreetInsider, Trading Concepts, Market Intelligence Center Alert, Zacks and InvestorPlace reported earlier on Five Point Holdings (FPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Five Point Holdings LLC (NYSE: FPH) (FRA: FP9) is a holding firm that is focused on owning and developing mixed-use and planned communities which combine commercial, residential, educational, retail and recreational elements with public amenities in the San Francisco, Los Angeles and Orange counties in California.

The firm has its headquarters in Irvine, California and was incorporated in 2009, on July 21st. Prior to its name change in May 2016, the firm was known as Newhall Holding Co. LLC. It operates as part of the real estate-development industry, under the real estate sector. The firm serves consumers in the United States.

The company operates through the Commercial, Great Park, San Francisco and Valencia segments. The Commercial segment comprises of the Five Point Gateway Campus located in the Great Park Neighborhoods. The Great Park segment includes neighborhoods being developed around and adjacent to the metropolitan Orange County Great Park. On the other hand, the San Francisco segment involves the San Francisco Shipyard and the Candlestick Point communities in San Francisco, California. The Valencia segment includes the Valencia community located along the Santa Clara River. The company generates most of its revenue from the sale of land sites to clients.

The enterprise sells commercial and residential land sites to commercial developers, homebuilders and commercial buyers. It also offers property development and management services.

The company recently announced its latest financial results, with its CEO noting that they remained focused on executing the company’s commercial property strategy. This will produce positive results for the firm, which will in turn, help create value for its shareholders.

Five Point Holdings (FPH), closed Monday's trading session at $2.25, off by 0.442478%, on 179,071 volume. The average volume for the last 3 months is 674,323 and the stock's 52-week low/high is $2.23/$8.20.

Vuzix Corp. (VUZI)

QualityStocks, PennyStocks24, MarketClub Analysis, Broad Street, TaglichBrothers, InvestorPlace, Fierce Analyst, TradersPro, TraderPower, BUYINS.NET, AwesomeStocks, OTCBB Journal, StockMarketWatch, StockGuru, Small Cap Firm, Money Morning, Schaeffer's, StockStreetWire, First Penny Picks, MarketBeat, StocksImpossible, StockWireNews, Leading Penny Stocks, The Street, StrategicTechInvestor, TopPennyStockMovers, Investing Futures, Investing Daily, OTCPicks,, Market Report, Weekly Wizards,, Trades Of The Day, Tiny Gems, PricelessPennyStocks, Zacks, StreetInsider, Stock Guru, Street Picks, StockOodles, Inside Investing Daily, S.A.Advisory, Stock Market Watch, Penny Stocks On Steroids, InvestorsUnderground, SmallCap Network, 24/7 Trader, Planet Penny Stocks, PennyOmega and StockHotTips reported earlier on Vuzix Corp. (VUZI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vuzix Corp. (NASDAQ: VUZI) (LON: 0LRL) (FRA: V7XN) is a growing dynamic firm that is involved in designing, manufacturing, marketing and selling augmented reality wearable display and computing devices.

The firm has its headquarters in West Henrietta, New York and was incorporated in 1997 by Paul J. Travers. Prior to its name change in September 2007, the firm was known as Icuiti Corp. It operates as part of the consumer electronics industry, under the technology sector. The firm serves enterprise and consumer markets around the globe, with a focus on those in Europe, the Asia-Pacific and North America.

The company has developed an intellectual property portfolio which includes over 200 patents and has decades of manufacturing know-how, proprietary processes, software, equipment and materials. It also has patents pending and numerous IP licenses in the Video Eyewear field. The company has offices in Tokyo, Japan; Oxford, United Kingdom; and Rochester, New York.

The enterprise’s products include its M400, M300XL and M4000 series of smart glasses; waveguide optics and related coupling optics; Vuzix Blade smart glasses; and Vuzix Shield smart glasses. It sells its products directly to commercial customers as well as through resellers, online stores and Vuzix operated web stores in Japan and Europe. The enterprise serves the medical, industrial, defense, security, commercial and first responder markets.

The company recently expanded its presence in the Asia-Pacific region after receiving a volume purchase order from HongKe Technology, its Chinese distribution partner. This will not only help extend its global consumer reach but also bring in additional revenues into the company and bolster its overall growth.

Vuzix Corp. (VUZI), closed Monday's trading session at $5.11, up 5.7971%, on 696,215 volume. The average volume for the last 3 months is 26,001 and the stock's 52-week low/high is $3.88/$16.20.

Zepp Health (ZEPP)

We reported earlier on Zepp Health (ZEPP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Zepp Health Corp. (NYSE: ZEPP) (BMV: ZEPPN) is a company focused on developing, manufacturing and selling smart wearable technological devices.

The firm has its headquarters in Hefei, the People’s Republic of China and was incorporated in December 2014 by Huang Wang. Prior to its name change, the firm was known as Huami Corp. It operates as part of the consumer electronics industry, under the technology sector. The firm serves consumers around the globe, with a focus on consumers in China.

The company is committed to connecting health with technology. It operates through the Xiaomi wearable products and self-branded products and others segments. The Xiaomi segment is comprised of the sale of Xiaomi-branded products while the self-branded products segment is comprised of self-branded products.

The enterprise has designed biometric and activity data-driven smart and fitness watches. The enterprise’s products include Amazfit ARC, Amazfit equator, Amazfit pace, Amazfit BIP and accessories, which include core trackers, sports bands, charging units, ear buds and watch straps. Its smart watches are water resistant and offer activity and sleep tracking, heart rate sensing, wireless syncing with mobile phones as well as smart notifications from mobile devices. The enterprise markets its products under the Amazfit brand, as it is the sole Xiaomi wearable product partner.

The company recently announced its latest financial results, with its CEO noting that they remained focused on extending and solidifying the company’s market position using its effective product strategy. This will bring in additional revenues and investments into the company while also bolstering its overall growth.

Zepp Health (ZEPP), closed Monday's trading session at $1.29, up 5.7377%, on 26,048 volume. The average volume for the last 3 months is 759,178 and the stock's 52-week low/high is $1.20/$9.73.

Stronghold Digital Mining Inc. (SDIG)

RedChip, QualityStocks, SmallCapVoice, Real Pennies, MarketBeat, StocksEarning, StockPicksNYC and OTC Markets Group reported earlier on Stronghold Digital Mining Inc. (SDIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Stronghold (NASDAQ: SDIG) on Friday provided an update on its previously announced agreement with NYDIG ABL LLC (“NYDIG”) and the Provident Bank (“BankProv”), to eliminate approximately $67 million in principal amount of debt outstanding under equipment financing agreements. Separately, Stronghold also announced its recent mutual termination and settlement of its data center hosting agreement. “We are pleased to have closed on a significant portion of our debt restructuring with NYDIG and look forward to eliminating the small remaining piece of this debt in the near future. These closings continue our meaningful transition towards a deleveraged company that can either sell power to the grid or use its low cost self-generated power to mine for Bitcoin,” said Greg Beard, co-chairman and chief executive officer of Stronghold. “We are also satisfied with the settlement of our prior hosting agreement, which provides us with improved operational control of our Bitcoin operations and a material uplift to our cash flow generation over the next two years, as well as significant optionality. Overall, we believe that we continue to make significant progress towards improving our balance sheet, liquidity and cost structure to deliver shareholder value.”

To view the full press release, visit

About Stronghold Digital Mining Inc.

Stronghold is a vertically integrated Bitcoin mining company with an emphasis on environmentally beneficial operations. Stronghold houses its miners at its wholly owned and operated Scrubgrass Plant and Panther Creek Plant, both of which are low-cost, environmentally beneficial coal refuse power generation facilities in Pennsylvania. For more information about the company, visit

Stronghold Digital Mining Inc. (SDIG), closed Monday's trading session at $1.04, up 9.4852%, on 762,233 volume. The average volume for the last 3 months is 218,889 and the stock's 52-week low/high is $0.8101/$35.795.

Blackboxstocks Inc. (BLBX)

QualityStocks, TradersPro, and MissionIR reported earlier on Blackboxstocks Inc. (BLBX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Blackboxstocks Inc. (NASDAQ: BLBX) is a development-stage firm that is engaged in the development and marketing of its financial technology and social media hybrid platform.

The firm has its headquarters in Dallas, Texas and was incorporated in 2011, on October 4th. Prior to its name change, the firm was known as SMSA Ballinger Acquisition Corp. It mainly serves consumers in the United States.

The company is a software-as-a-service firm with a growing base of users that spans over forty countries. Its web-based software uses predictive technology enhanced by AI to find unusual market activity and volatility that may cause a change in the price of options or stocks.

The enterprise provides users with a fully interactive social media platform that’s integrated into its dashboard, allowing users to exchange ideas and information efficiently and quickly via a common network. It also offers a live video/audio feature which enables members to broadcast on their own channels to share market insight and trading strategies within the Blackbox community. It serves as a tool for swing traders and day traders on the OTC markets, AMEX, NASDAQ and NYSE markets. The enterprise’s system monitors and analyzes more than 13,000 stocks on these markets simultaneously as its servers receive live feeds from the aforementioned markets.

The firm recently announced its latest financial results which show significant increases in its revenues. In addition to this, it crossed the threshold of 6,000 active paid subscribers. It is now focused on fueling product development, aggressive advertising and marketing with its goal being to drive subscriber growth. This may help extend its consumer reach as well as bring in more investors into the firm.

Blackboxstocks Inc. (BLBX), closed Monday's trading session at $0.649, up 15.8929%, on 218,941 volume. The average volume for the last 3 months is 3.171M and the stock's 52-week low/high is $0.525/$8.00.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, Schaeffer's, QualityStocks, Kiplinger Today, MarketBeat, StockMarketWatch, StocksEarning, StreetInsider, TradersPro, The Street, Trades Of The Day, TopPennyStockMovers, Daily Trade Alert, Early Bird, TraderPower, Wealth Insider Alert, BUYINS.NET, Zacks,, StockOodles, Jason Bond, InvestorsUnderground, The Online Investor, Cabot Wealth, PoliticsAndMyPortfolio, Profitable Trader Authority, Stock Beast, Wealth Daily, The Best Newsletters, Energy and Capital, The Wealth Report and Daily Market Beat reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Amazon announced on Monday that it had allocated $972 million for electrifying its vehicle fleet in Europe. This investment is set to grow the EV fleet of the online retailer from the current 3,000 vehicles to a minimum of 10,000 by 2025. Besides the 3,000 delivery vans already runs, the company also has 1,500 long-haul trucks running on li-ion batteries.

Amazon is taking these steps in order for all its operations to be carbon-neutral by 20240. While speaking at the launch of the electrification program, CEO Andy Jassy revealed that the hardest job the company faced was in taking its transportation division to net-zero. This goal would require sustained efforts as well as investment, and the company was willing to do everything it takes to attain the net-zero goals.

To this end, Amazon Europe plans to make a lot more deliveries using both e-bikes and personnel on foot. These additional decarbonization approaches are being made possible by the delivery stations located in central locations within densely populated metropoles and cities. These stations, dubbed micro-mobility hubs, currently exist in a host of European cities, such as Paris, London and Munich. In total, 20 cities across Europe have these hubs, and the plan is to roll more out and have double that number by the end of 2025.

The company says that the money it plans to inject into beefing up its EV fleet in Europe will be a catalyst for innovation within the electric vehicle industry and will add impetus to the efforts to develop a more robust EV charging network. This will subsequently encourage more players in the transportation industry to accelerate their plans of switching to more sustainable forms of energy and cut carbon emissions.

For entities such as Amazon, charging fleets of delivery vans is relatively easy because those vehicles converge at warehouses or depots overnight. Such an approach presents few hassles to charge these vehicles at night and have them ready to make their delivery runs during the day. However, the long-haul trucking segment is more challenging because the vehicles are on the road for most of the day and night, therefore making lengthy pit stops to recharge challenging.

Fortunately, plenty of electric vehicle manufacturers such as Workhorse Group Inc. (NASDAQ: WKHS) are ramping up their production. These increased numbers will have a corresponding positive effect upon accelerating plans to establish the needed infrastructure to support all those electric vehicles, including heavy-duty, long-haul trucks. Tesla has announced its intention to deliver a fully electric semi-trailer to Pepsi this December, and that could be the start of an avalanche of these semis hitting the road in different jurisdictions.

Workhorse Group Inc. (WKHS), closed Monday's trading session at $2.43, up 7.0485%, on 3,183,941 volume. The average volume for the last 3 months is 1.957M and the stock's 52-week low/high is $2.11/$7.80.

Anavex Life Sciences Corp. (AVXL)

MarketBeat, SmarTrend Newsletters, PennyStocks24, MarketClub Analysis, StocksEarning, BUYINS.NET, StockMarketWatch, QualityStocks, StreetInsider, StockOodles, The Street, Top Pros' Top Picks, PennyPro, TraderPower,, Investors Alley, InvestorPlace,, BestStocksDaily, Primoris Group, Schaeffer's, SmallCap Network, OTC Markets Group, Trading Desk, Top Stock Picks, TradersPro, PinnacleDigest, Pennybuster, StockRunway, Trade of the Week, Zacks, KingPennyStocks, Oakshire Financial, UltimatePennyStock, Investment House, Insider Wealth Alert, Dividend Opportunities, Wyatt Investment Research, AnotherWinningTrade, Market FN, StreetAuthority Financial, The Wall Street Transcript, Stock Research Newsletter, SmallCapGrowth, The Best Newsletters, smartOTC, CrazyStocks, VectorVest, Investor Ideas, Stock News Now, Investing Futures, Wall Street Elite, StockBlogs, Stock Beast, CustomerService, SquawkBoxStocks, Chatter Box Stocks, Buzz Stocks, Wealth Daily, TerrificPennyStocks, Barchart, AwesomeStocks, Daily Market Beat, SmallMovesBigGains, Tiny Gems, AimHighProfits, Power Profit Trades, Shah's Insights & Indictments, PhD-Trading, TopPennyStockMovers, Total Wealth, Jason Bond, SmallCapVoice, Money Morning, Promotion Stock Secrets, Market Intelligence Center, SpecialPennyStocks, MadMoneyPennyStocks, M2 Communications, TheStockAdvisors and JediPennyStocks reported earlier on Anavex Life Sciences Corp. (AVXL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company listed on the NasdaqCM. It is developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, pain, and different kinds of cancer. These includes Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) diseases. The Company is pursuing large markets with high unmet need through applying genetic precision medicine. Anavex Life Sciences has its corporate headquarters in New York, New York.

The Company’s lead drug candidate is ANAVEX®2-73 (blarcamesine). It recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate. It restores cellular homeostasis through targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease.

Additionally, ANAVEX®2-73 (blarcamesine) exhibited anticonvulsant, anti-amnesic, neuroprotective, as well as anti-depressant properties in animal models. This indicates its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research earlier awarded Anavex Life Sciences a research grant that fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease.

ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice. This includes cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.

Anavex Life Sciences Corp. (AVXL), closed Monday's trading session at $12.49, up 17.8302%, on 1,957,270 volume. The average volume for the last 3 months is 767,031 and the stock's 52-week low/high is $7.13/$23.73.

The QualityStocks Company Corner

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone deciding if an ER visit is warranted.”

To view the full article, visit

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.


HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Monday's trading session at $4.25, up 9.8191%, on 770,254 volume. The average volume for the last 3 months is 13,359 and the stock's 52-week low/high is $1.12/$6.74.

Recent News

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources Intersects Multiple Intersections including 108.16 g Ag eq/t (11.63 g Ag/t, 1.53% Zn and 0.36% Pb) over 111.26m in High-Grade Feeder Zone in Santa Barbara Target Area at the Iska Iska Silver-Tin Polymetallic Project, Potosi Department, Bolivia

This intersection in hole DSB-36, drilled 400m southeast of the Santa Barbara adit, includes higher-grade portions of:

180.29 g Ag eq/t (24.27 g Ag/t, 2.49% Zn and 0.73% Pb) over 24.13m .

197.54 g Ag eq/t (17.04 g Ag/t, 2.96% Zn and 0.58% Pb) over 11.82m .

211.34 g Ag eq/t (30.50 g Ag/t, 2.87% Zn and 0.76% Pb) over 6.02m .

Other significant intersections in this hole include :

101.31 g Ag eq/t (28.14 g Ag/t, 0.19% Zn, 0.55% Pb and 0.26% Cu) over 77.82m .

101.47 g Ag eq/t (23.88 g Ag/t, 1.08% Zn and 0.56% Pb) over 55.54m .

205.75 g Ag eq/t (20.69 g Ag/t, 0.15 g Au/t, 0.68% Zn and 0.75% Pb) over 22.75m .

136.82 g Ag eq/t (3.33 g Ag/t, 0.09 gAu/t, 1.72% Zn, 0.31% Pb and 0.07% Sn) over 78.39m including 478.26 g Ag eq/t (12.60 g Ag/t, 0.27 gAu/t, 5.61% Zn, 0.91% Pb and 0.28% Sn over 10.53m

203.26 g Ag eq/t (1.73 g Ag/t, 0.75% Zn and 0.42% Sn) over 12.22m .

The last sample in this 935.4m long hole returned 549.91g Ag eq/t (46.00 g Ag/t, 3.33% Zn, 2.27%Pb and 0.68% Sn) over 1.51m .

52% of this hole contained reportable intersections which collectively averaged 112.48 g Ag eq/t.

On-Strike Extension of High Grade Feeder Zone at Santa Barbara to South-Southeast now confirmed for an additional 400m and is open along strike.

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Monday's trading session at $2.54, up 1.9057%, on 13,359 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.74/$.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative change

Cannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countries

Flora Growth recently announced completion of its first shipments of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States

The company also recently reported a 604 percent YOY increase in revenues during the H1 reporting period, with a 547 percent gross profit increase during that period

Cannabis may be approaching a new watershed moment as Colombia pushes for national legalization of adult-use marijuana and the United States’ government undertakes long-anticipated discussion of whether to change the drug’s classification. The nearly unanimous approval of legislation to legalize and regulate adult-use cannabis by an initial committee reviewing bills in Colombia’s legislature, coupled with the president’s criticisms of decades-long prohibitionist policies and regulatory advances made by his predecessor, position the fertile country with a storied history on the front lines of the global war on drugs to become a major legal producer of cannabis and its derivatives ( ). In the United States, the President recently issued executive pardons to criminals convicted of marijuana possession in federal cases and asked federal health and law enforcement agencies to take a fresh look at the possibility of ending marijuana’s classification as an illicit substance, creating energy for cannabis stocks in the country ( ). International cannabis company Flora Growth (NASDAQ: FLGC) is headquartered in Fort Lauderdale, Florida but operates its cultivation from a 100-hectare (about 247-acre) licensed farming facility in northern Colombia where it develops cannabis products and then ships them into international markets or to its GMP-certified facility in the nation’s capital for transformation into consumer ready goods.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Monday's trading session at $0.591, up 4.9734%, on 299,939 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.54/$5.6092.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, has developed an AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles. “The company’s Fr8App B2B marketplace is its flagship product in a suite powered by AI and machine learning technology that helps connect shippers with qualified carriers as a real-time broker portal… In the company’s Q2 2022 financial report, Fr8Tech noted that quarterly revenue for the period ended June 30 grew 60% over the Q1 report and was up 45% for the period YoY, establishing a new record for the company,” a recent article reads. “The growth reflects greater traction in each of our dedicated capacity product, Fr8Fleet, and our U.S. domestic Fr8App services… Fr8App offers many advantages, including time and cost savings, that benefit shippers and carriers. Even when macro-economic challenges persist, goods still need to be delivered in a timely and costly manner, and Fr8App makes the whole process easier. As such, we continue to broaden our customer reach,” Fr8Tech CEO Javier Selgas is quoted as saying. To view the full article, visit

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Monday's trading session at $0.45, up 3.4245%, on 31,158 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.356/$8.734.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. This change often results in myriad consequences ranging from emotional and somatic changes to cognitive impairment and physical symptoms… In most cases, concussion symptoms resolve within a few days or weeks as the damaged pathways rebuild and strengthen through repetition, use and cleanup of cell debris. However, there has been growing concern that mTBI may be associated with long-term consequences, particularly due to repeated or multiple head impacts,” explains a recent article. “Odyssey has so far evidenced, through animal studies, that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation caused by concussion while simultaneously restoring proper blood flow. The drug is intended to be administered immediately after a concussive episode, effectively mitigating the effects a blow or jolt might have on the brain and its functions.” To view the full article, visit . Heart disease, which is estimated to take around 17.9 million lives annually , is among the leading causes of death across the world. This condition commonly affects people aged 20 and older across the united States, with one American suffering a heart attack every 40 seconds. In total, roughly 800,000 individuals suffer heart attacks every year. Although heart diseases such as coronary artery disease cannot be cured, early detection can allow for the management of symptoms to reduce a patient’s chances of having a heart attack. Researchers have now developed software that could allow physicians to detect heart disease in only 60 seconds by analyzing the arteries and veins in the eye. The AI tool leverages machine learning to study the web of veins and arteries that crisscross the retina, measuring the total area these blood vessels cover, their width and how bendy they are.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Monday's trading session at $0.385, up 21.0692%, on 217,972 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.11/$0.64.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

There has been a seismic shift in public perception toward hallucinogenic drugs such as psilocybin in the past couple of years. After decades of criminalization and little to no research on the effects of psychedelics, the substances have seen a significant surge in interest among the scientific community. Initial research has found that psychedelic drugs seem to have positive effects on mental health, especially when paired with psychotherapy. Researchers have found that psychedelic-assisted psychotherapy can alleviate the symptoms of mental health conditions including treatment-resistant depression, post-traumatic stress disorder (PTSD) and eating disorders. Some have called it the psychedelic renaissance , stating that hallucinogenic drugs have the potential to revolutionize psychiatry as we know it. In an upcoming documentary from ALTRD.TV, leading industry experts will discuss the resurgence of psychedelic research and the impact hallucinogenic treatments are expected to have on psychiatry. The documentary, titled “ Open Minds; Exploring Psychedelic Medicine , ” will involve psychedelic experts from MAPS, the Chopra Foundation, Cybin Inc. and the Mckenna Academy of Natural Philosophy, among others. Strongman, who has worked with patients who benefited from groundbreaking MAPS research, said that the documentary will help raise awareness of alternative treatments for mental illnesses. This documentary offers a different way to disseminate information about psychedelics to complement what companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) have been doing to raise public awareness.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Monday's trading session at $0.03522, up 0.628571%, on 18,766 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.204.

Recent News


The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

LQwD is focused on creating enterprise-grade infrastructure to drive bitcoin adoption and, develop institutional-grad services supporting the Lightning Network functionality, transaction capabilities, and bring BTC to scale

LQwD Lightning Network nodes include Canada, France, Japan, England, Japan-Osaka, Australia, Italy, Indonesia, Bahrain, South Africa, South Korea, Sweden, Singapore, Hong Kong, Brazil, Germany, India, Ireland, and US-West

Currently servicing 17 countries, LQwD plans to increase reach to 24 worldwide by the end of the current quarter

The global blockchain market was valued at US $4.67 billion in 2021 and is projected to reach US $7.18 billion in 2022, and then US $163.83 billion by 2029

LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption and develop institutional-grade services that support the Lightning Network's functionality, transaction capabilities, user adoption and utility, and scale bitcoin. The company'splatform-as-a-solution (“PaaS”), enables Lightning Network node hosting and channel management and serves as a Liquidity Service Provider (“LSP”) for merchants – allowing for blockchain transactions worldwide.

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.


The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Monday's trading session at $0.0558, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0475/$0.672.

Recent News

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

New research has found that the ongoing prohibition of cannabis at the federal level is getting between safe products and consumers. The research was conducted for one year by investigators at Arizona State University, led by Dr. Maxwell Leung. The objective of the research was to determine the prevalence of a range of contaminants in lab-tested marijuana. Currently, marijuana is still classified as a Schedule I substance under the Controlled Substances Act, which means that it isn’t subject to USDA or FDA regulations that are applied to legal products. This ongoing prohibition has left many states to work out how they can best ensure the safety of cannabis products sold in their jurisdictions. Without those federal guidelines, states and individual companies such as American Cannabis Partners are left to create and implement their own product purity standards and yet the ideal would be for all actors to adhere to the same quality standards.

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News


Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Google recently announced the closure of its Google Stadia gaming business, a decision which may have partly been underpinned by the dearth of new gaming titles available on the platform

Content has remained a crucial driver of success within the iGaming industry, a factor which Golden Matrix Group have sought to cater to

Through their proprietary GM-X turnkey solution, the company provides its licensing partners with access to upward of 10,000 games drawn from over 25 gaming studios

On November 19, 2019, Google made an announcement that was set to potentially change the face of the gaming universe as we know it. Google was set to launch their Google Stadia cloud-based gaming platform, a revolutionary system which bypassed the erstwhile console gaming industry, rather allowing gamers to access their games via streaming across a host of compatible TVs, computers, and mobile devices. However, and whilst the idea was game changing in nature, the execution lagged far behind. Google Stadia recently announced that it would officially shut up shop on January 18, 2023, bringing a close to the internet giant’s push into online gaming ( ). However, a key rationale which may have led to the early closure of Google Stadia may also be the same factor dictating the potential failure or success of the iGaming business – content. A key issue pinpointed as the reason behind Google Stadia’s relative lack of success was the gaming company’s economic model: subscribers to Stadia Pro would be given a handful of games each month that they could access for as long as they had a subscription – similar to PlayStation Plus – whereas the majority of games required a separate purchase. As a result, gamers expecting to benefit from reams of available games were forced to deal with relatively limited selections. The situation was only further exacerbated only 14 months post the launch of the gaming system, when Google decided to shutter its internal game development studio; the company would opt to switch their focus towards building out a gaming content aggregator platform rather than an original content distributor as originally envisioned ( ). Whilst Google’s exit from the online gaming space inevitable captured the headlines, it is an iteration of a broader trend affecting the iGaming space – one which has seen new platforms opt towards adopting a white-labelled gaming solution whilst directing their efforts and resources towards marketing and promotional endeavours. Golden Matrix Group (NASDAQ: GMGI) , a developer and licensor of online gaming platforms, systems, and gaming content, has sought in turn to carve out its own niche within the content aggregation and B2B iGaming space in a move designed to capitalize on the ongoing industry shift. Golden Matrix Group purveys its services to the B2B gaming industry through its proprietary GM-X turnkey solution, a complete software package designed to support online gaming businesses. The white-labelled service provided third party gaming platforms with access to GMGI’s expansive portfolio of over 10,000 games, ranging from online slots, casino table games, live operator games, and more drawn from Golden Matrix Group’s partnership with more than 25 gaming studios.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Monday's trading session at $2.63, off by 2.5926%, on 31,123 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.51/$10.72.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton Technologies (NASDAQ: CPTN) , a Silicon Valley innovator and leader in high-performance lidar solutions, announced that LidarSwiss Solutions GmbH is deploying its Sora(TM) lidar technology in the company’s drone-based mapping and analytics solution, which is available for infrastructure management and engineering design applications. The full Nano P60 system is on display at the INTERGEO event, held Oct. 18–20, 2022, in Germany. Based in Switzerland, LidarSwiss provides high-performance unmanned aerial vehicle (“UAV”)-based lidar solutions that feature high-fidelity mapping and real-time processing, a key solution for engineers, forestry managers and urban planners. The Nano P60 platform has been used to map and analyze flood plains, highways, power lines and areas for site development in more than 20 cities in Asia, Europe and Australia. “We are proud to be supporting LidarSwiss and its customers with our lidar technology to unlock applications such as 3D modeling for BIM, historical site mapping, terrain modeling for heavy vegetation areas, volumetric calculations for mining, power line inspection and forestry mapping,” said Cepton Technologies director of product management and marketing Klaus Wagner in the press release. “Our Sora lidar is a one-of-a-kind line scanner that combines high frame rate and long range. Powered by Cepton’s proprietary lidar technologies, it is compact, lightweight and rotation free, making it ideal for small UAV applications.” To view the full press release, visit

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Monday's trading session at $2.33, off by 8.6275%, on 351,988 volume. The average volume for the last 3 months is 351,988 and the stock's 52-week low/high is $1.01/$80.16.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN) , a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration of effect, compared to oral psilocybin. CYB003 has the potential to reduce time in the clinic, which could allow more scalability and access for this treatment. As a randomized, double-blind, placebo-controlled study, the current phase 1/2a trial will evaluate individuals with moderate to severe major depressive disorder (‘MDD’),” a recent article reads. “To commence dosing in our first in-human phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months. Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients, and today we have moved one step closer,” Cybin CEO Doug Drysdale is quoted as saying. To view the full article, visit

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Monday's trading session at $0.5514, off by 3.6014%, on 926,738 volume. The average volume for the last 3 months is 917,274 and the stock's 52-week low/high is $0.3903/$2.355.

Recent News

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

  • Data Protection has increasingly become a focus around the globe, with the United States and Europe recently agreeing to implement a joint data privacy framework
  • With one small company said to be successfully hacked every 19 seconds, losses attributed to data breaches in the United Kingdom alone amount to over £4 billion per annum
  • Reklaim has centred its business model around enabling users to reclaim their data, delete it or in its stead, monetize it
  • The company recently entered a non-binding letter of intent to purchase US-based Multimedia Lists to expand its top-line revenue and profitability further

In 2004, Philip Cummings pleaded guilty to one of the most significant identity theft cases in the United States. Cummings worked at a desk job at Teledata Communications, Inc. in Long Island, New York, helping companies run routine credit checks. On the day he resigned, Cummings packed up his desk – along with the passwords of 33,000 of the company’s clients. Cummings would go on to sell the sensitive data to criminals who would use it to drain bank accounts and open new lines of credit, with total losses pegged by the Government at upwards of $100 million ( While enormous, the scale of losses generated by Cummings’ actions is increasingly trivial in today’s online world. In the United Kingdom alone, one small business is hacked every 19 seconds, with data breaches driven by identity theft reportedly costing the nation over £4 billion in losses every year ( It is this growing phenomenon that companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) seek to tackle. Reklaim (OTCQB: MYIDF) (TSX.V: MYID), the destination for consumers to access and reclaim their data, will be presenting at the 15th annual LD Micro Main Event, which will be held Oct. 25–27, 2022, in Las Vegas. Reklaim CEO Neil Sweeney will present during the event; his presentation is slated to begin at 9 a.m. on Oct. 26. PT. Sweeney will also be available for one-on-one meetings with potential investors attending the event. According to the announcement, the LD Micro Main Event is designed to facilitate learning, connecting and enjoying each other, with a company official noting that it is “much more fun than sitting next to your computer.” The three-day event agenda will include presentations by more than 200 companies. “Data privacy regulations, which prevent the sale of unconsented data, are suffocating the revenues of legacy data companies whose business models are dependent upon this type of transaction," said Reklaim CEO Neil Sweeney in the press release. “As more legislation is passed, the need for Fortune 500 companies to find a new supplier of consented data at scale grows. Reklaim is the only destination for brands and companies to source high-fidelity, first-party consented profiles that do not violate data privacy regulations. We're growing organically and through acquisition and have firmly established a first-mover advantage in this $257 billion market. I look forward to discussing our opportunities with investors at the LD Micro Main Event." To view the presentation, visit To view the full press release, visit

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online ( and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Monday's trading session at $0.04229, off by 23.5746%, on 57,000 volume. The average volume for the last 3 months is 57,000 and the stock's 52-week low/high is $0.0387/$0.3859.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.